Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572729 | 1.00 | TDP1 (0.50) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12954445 | 0.85 | KMT2A (0.51) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5509505 | 0.84 | ALDH1A1 (0.52) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3928524 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14384259 | 0.84 | ALDH1A1 (0.52) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11938125 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3919839 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5509506 | 0.84 | ALDH1A1 (0.52) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4019893 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1531400 | 0.83 | TYR (0.58) | TDP1ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247452-B2 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| EP-1523471-B1 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080033042-A1 | UREA-AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| US-7262220-B2 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| WO-2004007437-A9 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1513800-B1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-7049341-B2 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1523471-A1 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1513800-A1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004007437-A1 | UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003104188-A1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | TDP1 3454/4885ALDH1A1 230/4885MAPT 4812/4885 |
| US-20040087659-A1 | Urea- and urethane-substituted acylureas, process for their preparation and their use | UGP2, UGDH, UGT1A1 | TDP1 1936/4885ALDH1A1 143/4885MAPT 2385/4885 |
| US-20080033042-A1 | UREA-AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE | UGP2, UGDH, UMPS | TDP1 2478/4885ALDH1A1 239/4885MAPT 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.